nach oben

Erschienen in:

01.03.2007 | Original Article

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men

verfasst von: Carsten Stephan, Chuanliang Xu, Henning Cammann, Markus Graefen, Alexander Haese, Hartwig Huland, Axel Semjonow, Eleftherios P. Diamandis, Mesut Remzi, Bob Djavan, Mark F. Wildhagen, Bert G. Blijenberg, Patrik Finne, Ulf-Hakan Stenman, Klaus Jung, Hellmuth-Alexander Meyer

Erschienen in: World Journal of Urology | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Use of percent free PSA (%fPSA) and artificial neural networks (ANNs) can eliminate unnecessary prostate biopsies. In a total of 4,480 patients from five centers with PSA concentrations in the range of 2–10 ng/ml an IMMULITE PSA-based ANN (iANN) was compared with other PSA assay-adapted ANNs (nANNs) to investigate the impact of different PSA assays. ANN data were generated with PSA, fPSA (assays from Abbott, Beckman, DPC, Roche or Wallac), age, prostate volume, and DRE status. In 15 different ROC analyses, the area under the curve (AUC) in the PSA ranges 2–4, 2–10, and 4–10 ng/ml for the nANN was always significantly larger than the AUC for %fPSA or PSA. The nANN and logistic regression models mostly also performed better than the iANN. Therefore, for each patient population, PSA assay-specific ANNs should be used to optimize the ANN outcome in order to reduce the number of unnecessary biopsies.

Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol 162:293–306PubMedCrossRef

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239–2246PubMedCrossRef

Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1–antichymotrypsin. Clin Chem 37:1618–1625PubMed

Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alpha 1–antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222–226PubMed

Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547PubMedCrossRef

Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW (1996) Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48:55–61PubMedCrossRef

Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 104:993–1003PubMedCrossRef

Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL (1999) Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54:220–224PubMedCrossRef

Jung K, Stephan C, Elgeti U, Lein M, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA (2001) Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/l—are they useful tools for early detection and screening of prostate cancer? Int J Cancer 93:759–765PubMedCrossRef

10.

Lee CT, Scardino PT (2001) Percent free Prostate-specific antigen for first-time prostate biopsy. Urology 57:594–598PubMedCrossRef

11.

Stephan C, Lein M, Jung K, Schnorr D, Loening SA (1997) Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? [Letter]. J Urol 157:1371PubMedCrossRef

12.

Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H (1997) Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 158:2188–2192PubMedCrossRef

13.

Mettlin C, Chesley AE, Murphy GP, Bartsch G, Toi A, Bahnson R, Church P (1999) Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 39:153–158PubMedCrossRef

14.

Stephan C, Lein M, Jung K, Schnorr D, Loening SA (1997) The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79:104–109PubMedCrossRef

15.

Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA (1998) The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol 82:231–236PubMed

16.

Carlson GD, Calvanese CB, Partin AW (1998) An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 52:455–461PubMedCrossRef

17.

Virtanen A, Gomari M, Kranse R, Stenman UH (1999) Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45:987–994PubMed

18.

Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, Zhang Z (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml. Urology 56:1000–1006PubMedCrossRef

19.

Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M (2002) Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20:921–929PubMedCrossRef

20.

Finne P, Finne R, Auvinen A, Juusela H, Aro J, Maattanen L, Hakama M, Rannikko S, Tammela TL, Stenman U (2000) Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 56:418–422PubMedCrossRef

21.

Remzi M, Anagnostou T, Ravery V, Zlotta A, Stephan C, Marberger M, Djavan B (2003) An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 62:456–460PubMedCrossRef

22.

Stephan C, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Lein M, Schnorr D, Sinha P, Loening SA (2002) An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation. Int J Cancer 99:466–473PubMedCrossRef

23.

Kalra P, Togami J, Bansal BSG, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS (2003) A neurocomputational model for prostate carcinoma detection. Cancer 98:1849–1854PubMedCrossRef

24.

Partin AW, Murphy GP, Brawer MK (2000) Report on prostate cancer tumor marker workshop 1999. Cancer 88:955–963PubMedCrossRef

25.

Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, Schürenkämper P, Loening SA (1996) Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 42:1026–1033PubMed

26.

Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A (2002) Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls. Eur Urol 42:577–582PubMedCrossRef

27.

Patel D, White PA, Milford WA (2000) A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 85:686–689PubMedCrossRef

28.

Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L (1996) Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 48(Suppl):10–15PubMedCrossRef

29.

Yurdakul G, Bangma C, Blijenberg B, van Zelst B, Wildhagen M, van der KT, Schroder F (2002) Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol 42:154–158PubMedCrossRef

30.

Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, Sinha P, Loening SA, Jung K (2002) Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48:1279–1287PubMed

31.

Hodge KK, McNeal JE, Terris MK, Stamey TA (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142:71–74PubMed

32.

Romics I (2004) The technique of ultrasound guided prostate biopsy. World J Urol 22:353–356PubMedCrossRef

33.

Woodrum D, York L (1998) Two-year stability of free and total PSA in frozen serum samples. Urology 52:247–251PubMedCrossRef

34.

Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH (2001) Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 88:545–550PubMedCrossRef

35.

Jung K, Stephan C, Lein M, Brux B, Sinha P, Schnorr D, Loening SA (2001) Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms—What has to be considered? Prostate 46:307–310PubMedCrossRef

36.

Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA (2000) Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9:1133–1147PubMed

37.

Schroder FH, Kranse R (2003) Verification bias and the prostate-specific antigen test—is there a case for a lower threshold for biopsy? N Engl J Med 349:393–395PubMedCrossRef

38.

Roehl KA, Antenor JA, Catalona WJ (2002) Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol 168:922–925PubMedCrossRef

39.

Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L (1996) Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 7:3–16PubMedCrossRef

40.

Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches. Cancer 91:1636–1642PubMedCrossRef

Titel: Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men
verfasst von: Carsten Stephan
Chuanliang Xu
Henning Cammann
Markus Graefen
Alexander Haese
Hartwig Huland
Axel Semjonow
Eleftherios P. Diamandis
Mesut Remzi
Bob Djavan
Mark F. Wildhagen
Bert G. Blijenberg
Patrik Finne
Ulf-Hakan Stenman
Klaus Jung
Hellmuth-Alexander Meyer
Publikationsdatum: 01.03.2007
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 1/2007
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-006-0132-9

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men

Abstract

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

Basic principles of anatomy for optimal surgical treatment of prostate cancer

Gender discrepancies in the diagnosis of renal cortical tumors

Endoscopic extraperitoneal radical prostatectomy: the University of Leipzig experience of 1,300 cases

Molecular staging of prostate cancer in the year 2007

Biopsy standards for detection of prostate cancer

Treatment of localized prostate cancer

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie